GoodRx Holdings, Inc. (GDRX) operates a consumer-focused digital healthcare platform that helps people compare prices and save on prescription drugs, generating revenue through pharmacy benefit managers, pharma manufacturer solutions, subscriptions, and telehealth. The company is a stock, not an ETF. The central $4.00 target represents the average of 13 current analyst price targets from named firms. The low-to-high range remains unusually wide, from $2.65 to $5.00, reflecting real disagreement about the company's trajectory. The most bullish views come from TD Cowen, Wells Fargo, Citi, and Leerink Partners, all at $5.00, while Bank of America Securities holds the lowest target at $2.65. Other firms sit in the middle: Morgan Stanley and Goldman Sachs at $4.00, UBS at $3.75, and Mizuho, Deutsche Bank, and Barclays around $3.00 to $4.00. This dispersion highlights a genuinely split Street, with roughly five analysts rating the stock a buy, about eight a hold, and two a sell. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Constructive analysts highlight improving fundamentals and GLP-1 momentum, while cautious ones focus on structural pressure in the core prescription-transaction business and a lower long-term growth outlook.
With shares recently trading around $3.47, the $4.00 target implies roughly 15% upside. That remains a modest required move, though it sits near the top of the stock's 52-week range of roughly $1.77 to $3.89. The path depends on sustained execution in the faster-growing Pharma Direct and pharma-manufacturer-solutions segments, which analysts increasingly view as the next leg of growth as the legacy prescription-discount business navigates a take-rate reset. Valuation is not cheap on trailing earnings—the trailing price-to-earnings ratio is roughly 70 and EPS over the past year is only about $0.05—so the target rests more on future margin expansion and top-line reacceleration than on current profitability. From what I see, the stock would need to clear its recent high to reach the target.
Several factors could help GDRX move higher. A wave of mid-2026 target increases from TD Cowen, Wells Fargo, Citi, and Leerink Partners—several lifted to $5.00—signals improving sell-side confidence in fundamentals. Demand tied to GLP-1 weight-loss drugs has been cited as a catalyst for the Pharma Direct business, and management has emphasized direct relationships with pharmaceutical manufacturers. Revenue over the trailing twelve months is roughly $785 million with about $296 million in cash, and the company generated meaningful adjusted EBITDA, giving it flexibility to reinvest. I’m watching this closely as execution in these areas could provide the needed lift.
The main risks are structural. The core prescription-transaction business has faced pressure from a reset in take rates, and net income of roughly $16 million on $785 million in revenue leaves thin profit margins. Competition from other price-comparison platforms, PBM dynamics, and pharmacy-industry headwinds all weigh on the outlook. The analyst base is deeply divided, and earlier in 2026 Deutsche Bank, Jefferies, and JPMorgan all moved more cautious, while Bank of America and Barclays carried sell ratings. A guidance cut, slower Pharma Direct growth, or renewed take-rate pressure could compress the multiple and keep shares below $4.00.
Technically, shares have recovered substantially from the 52-week low near $1.77 but remain below the 52-week high near $3.89. That prior high is a meaningful resistance level, and $4.00 itself is a natural psychological round-number barrier sitting just above it. On the downside, the $3.40 to $3.50 area has acted as a near-term zone, with deeper support further below near the prior lows. The stock's five-year beta around 1.66 indicates above-average volatility, so moves toward the target are unlikely to be smooth. One thing that stands out is how the stock's volatility could create both opportunities and challenges along the way.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ. Investors should watch the next quarterly earnings release and updated guidance, any further analyst target revisions, and developments in the Pharma Direct and GLP-1-related businesses. Changes in prescription take rates, PBM relationships, and competitive pricing activity are equally important, as are broader healthcare-policy signals that could affect drug pricing and reimbursement.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I rely on these signals in my own process to discover new opportunities, keep an eye on existing positions, and identify shifting trends more efficiently than manual review allows. For investors following GoodRx, combining fundamental research with AI-generated technical signals can add a useful second perspective on entry and exit timing.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for GDRX moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 46 of the 56 cases the stock moved lower. This puts the odds of a downward move at 82%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GDRX as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for GDRX turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
GDRX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
GDRX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GDRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +4.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where GDRX advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 124 of 147 cases where GDRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. GDRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.849) is normal, around the industry mean (4.523). GDRX has a moderately high P/E Ratio (58.500) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.494) is also within normal values, averaging (6.105).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry